

Compass Opioid Prescribing + Treatment Guidance Toolkit



Recommended Screening Tools for Pain + Opioid Risk Management

Acute Pain (Short-Term Use): Initial Visit

- + PEG-3 (Pain, Enjoyment, General Function)
- + Interview questions: personal and family history of substance use disorders
- + Screening Portion of Screening, Brief Intervention, and Referral to Treatment
- + Online Prescription Database (aka Prescription Drug Monitoring Program varies by state)

Chronic Pain (Long-Term Use): Initial Visit(s)

- + <u>PEG-3</u> (Pain, Enjoyment, General Function)
- + Screening Portion of Screening, Brief Intervention, and Referral to Treatment
- + Tobacco \rightarrow <u>Fagerström Test</u> Alcohol \rightarrow <u>AUDIT</u> Cannabis \rightarrow <u>CUDIT-R</u> Drugs \rightarrow <u>DAST-10</u>

Interview Questions:

- + Personal and family history of substance use disorders
- + Personal history of psychiatric or mood problems
- + Adverse Childhood Experience questionnaire (<u>ACE</u>) for trauma
- + <u>PHQ-2</u> \rightarrow <u>PHQ-9</u> if affirmative for depressed mood; <u>GAD-7</u> if affirmative for anxiety
- + <u>STOP-BANG</u> for obstructive sleep apnea risk
- + Online Prescription Database (aka Prescription Drug Monitoring Program varies by state)
- + Drug testing by definitive method: GC/MS or LC/MS-MS
- + Screener and Opioid Assessment for Patients with Pain Revised (SOAPP-R)
 - + Alternatives: Risk Index for Overdose or Serious prescription Opioid-induced Respiratory Depression (<u>RIOSORD</u>), Opioid Risk Tool (<u>ORT</u>)

Chronic Pain (Long-Term Use): Follow-Up Visits

- + Five A's: Activities (function), Analgesia, Affect (mood), Adverse Effects, Aberrancies
- + <u>PEG-3</u> (Pain, Enjoyment, General Function)
- + Current Opioid Misuse Measure (COMM)



Compass Opioid Prescribing + Treatment Guidance Toolkit



- + <u>PHQ-2</u> \rightarrow <u>PHQ-9</u> if affirmative for depressed mood; <u>GAD-7</u> if affirmative for anxiety
- + Online Prescription Database (aka Prescription Drug Monitoring Program varies by state)
- + Drug screening by immunoassay, testing by definitive method: GC/MS or LC/MS-MS

For Other Conditions When Suggested by History

- + Post-Traumatic Stress Disorder: PTSD Check List (PCL-C)
- + Bipolar Disease: Mood Disorder Questionnaire (MDQ)
- + Attention Deficit Hyperactivity Disorder: Adult ADHD Self-Report Scale (ASRS)
- + Psychosis: Psychosis Screener (PS)
- + Insomnia: Sleep Condition Indicator (SCI)
- + Suicidality: Patient Safety Screener (PSS-3)

This material was prepared by the lowa Healthcare Collaborative, the Opioid Prescriber Safety and Support contractor, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS.

Developed in collaboration with Stader Opioid Consultants.